On October 6, 2026 Nurix Therapeutics, Inc. (Nasdaq: NRIX) reported that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton’s tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study is being conducted under the global collaboration between Nurix and Roche and is designed to evaluate the safety, tolerability and clinical activity of bexobrutideg in combination with venetoclax, a BCL2 inhibitor. Data from the trial are expected to inform future registrational development strategies across lines of therapy in CLL, including evaluating bexobrutideg in combination with the anti-CD20 antibodies rituximab and obinutuzumab across multiple cohorts of patients with relapsed or refractory and previously untreated CLL, and potential expansion into other B-cell malignancies.
"The initiation of this study marks another important milestone in our effort to realize the full potential of bexobrutideg across B-cell malignancies," said Arthur T. Sands, M.D., Ph.D., chief executive officer of Nurix. "Combination therapies are becoming increasingly important in the treatment of CLL, especially in earlier lines of therapy, and we believe bexobrutideg’s differentiated mechanism of action, robust single-agent activity and favorable tolerability make it an attractive partner for combination approaches to deliver deep, durable responses with fixed-duration therapy."
About Bexobrutideg (NX-5948)
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.
Bexobrutideg is currently being evaluated in a broad clinical development program in patients with chronic lymphocytic leukemia (CLL), including the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed/refractory CLL previously treated with covalent and noncovalent BTKi and a BCL2i; the DAYBreak CLL-306 clinical trial (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg to pirtobrutinib in patients with relapsed/refractory CLL previously treated with a covalent BTKi; the NX-5948-203 Phase 1b/2 clinical trial (NCT07520006), assessing the combination of bexobrutideg with venetoclax in patients with relapsed/refractory CLL and potentially treatment-naïve CLL; and the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.
(Press release, Nurix Therapeutics, OCT 6, 2026, View Source [SID1234673248])